Skip to main content

IDWeek 2023 Main banner

Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

259 Views

047. COVID-19: Treatment: Thursday, 12:15 - 1:30 p.m.

Poster Session: COVID-19: Treatment

(524) Hepatic Safety of Remdesivir Across Phase 3 Placebo-controlled COVID-19 Studies

Thursday, October 12, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Lindsey Force, MD (she/her/hers)

Sr Director, Patient Safety
Gilead Sciences, Inc.
Foster City, California, United States

Co-Author(s)

CB

Chris Blair, MS

Gilead Sciences, Inc.
Foster City, California, United States
JD

Joshua Duckworth, PhD

Gilead Sciences, Inc.
Foster City, California, United States
MA

Mazin Abdelghany, MD

Gilead Sciences, Inc.
Foster City, California, United States
NN

Ngoc-Quyen Nguyen, PharmD

Gilead Sciences, Inc.
Foster City, California, United States
RH

Robert H. Hyland, DPhil

Gilead Sciences, Inc.
Foster City, California, United States
SD

Santosh Davies, MD

Gilead Sciences, Inc.
Foster City, California, United States
SC

Shuguang Chen, PhD

Director
Gilead Sciences, Inc
Foster City, California, United States
YZ

Yang Zhao, PhD

Gilead Sciences, Inc.
Foster City, California, United States
OF

Olivia Fu, MD

Gilead Sciences, Inc.
Foster City, California, United States